Role of APRIL (TNFSF13) polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese

Rheumatology

Volumn 46, Issue 5, 2007, Pages 776-782

  Kawasaki, A ^a,b   Tsuchiya, N ^b   Ohashi, J ^a   Murakami, Y ^c   Fukazawa, T ^d   Kusaoi, M ^d   Morimoto, S ^d   Matsuta, K ^e   Hashimoto, H ^f   Takasaki, Y ^d   Tokunaga, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

^e Matsuta Clinic   (Japan)

^f Juntendo University Hospital   (Japan)

Author keywords

APRIL (TNFSF13); Genetics; Polymorphism; Susceptibility; Systemic lupus erythematosus

Indexed keywords

APRIL PROTEIN; HYBRID PROTEIN; MESSENGER RNA; PROTEIN TNFSF12; PROTEIN TWEAK; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER 12; UNCLASSIFIED DRUG; LIGAND; TNFSF12 PROTEIN, HUMAN; TNFSF13 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE FREQUENCY; GENE REPLICATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HOMOZYGOTE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; ASIAN; BLOOD; CLINICAL TRIAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; JAPAN; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; LIGANDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RNA, MESSENGER; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; TUMOR NECROSIS FACTORS;

EID: 34347209117     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem019     Document Type: Article

References (53)

1. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL et al. APRIL, a new ligand of to tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-90.
2. Kelly K, Manos E, Jensen G, Nadauld L, Jones DA. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 2000;60:1021-7.
3. Moore PA, Belvedere O, Orr A et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3.
4. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56.
5. Gross JA, Johnston J, Mudd S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9.
6. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997;278:138-41.
7. Yu G, Boone T, Delaney J et al. APRIL and TALL-I and receptors BCMA and TACI: System for regulating humoral immunity. Nat Immunol 2000;1:252-6.
8. Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-11.
9. Yan M, Brady JR, Chan B et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001;11:1547-52.
10. Ingold K, Zumsteg A, Tardivel A et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005;201:1375-83.
11. Litinskiy MB, Nardelli B, Hilbert DM et al DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
12. Ng LG, Sutherland AP, Newton R et al B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-17.
13. Stein JV, Lopez-Fraga M, Elustondo FA et al. APRIL modulates B and T cell immunity. J Clin Invest 2002;109:1587-98.
14. Planelles L, Carvalho-Pinto CE, Hardenberg G et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Call 2004;6:399-408.
15. Castigli E, Scott S, Dadeoglu F et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004;101:3903-8.
16. Ramanujam M, Wang X, Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116:724-34.
17. Mackay F, Woodcock SA. Lawton P et al Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
18. Khare SD, Sarosi I, Xia XZ et al Severe B cell hyperplasia and autcimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97:3370-5.
19. Seshasayse D, Valdez P, Yan M, Dixit VM, Tumas D, Grawal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-88.
20. Gross JA, Dillon SR, Mudd S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302.
21. Kayagaki N, Yan M, Seshasayee D et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002;17:515-24.
22. Wang H, Marsters SA, Baker T et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001;2:632-7.
23. Zhang J, Roschke V, Baker KP et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
24. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9.
25. Tan SM, Xu D, Roschke V et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48:982-92.
26. Koyama T, Tsukamoto H, Miyagi Y et al. Raised serum APRIL levels in patients with systemic lupus erythematosus, Ann Rheum Dis 2005;64:1066-7.
27. Moser KL, Ness BR, Salmon JE et al. Genome scan of human systemic lupus erythematosus: Evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci USA 1998;95:14869-74.
28. Cantor RM, Yuan J, Napier S et al. Systemic lupus erythematosus genome scan: Support for linkage at 1q23, 2q33, 16q12-13, and 17q21-23 and novel evidence at 3p24, 10q23-24, 13q32, and 18q22-23. Arthritis Rheum 2004;50:3203-10.
29. Johansson CM, Zunec, R, Garcia MA et al. Chromosome 17p12-q11 harbors susceptibility loci for systemic lupus erythematosus. Hum Genet 2004;115:230-8.
30. Nath SK, Kelly JA, Namjou B et al. Evidence for a susceptibility gone, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Am J Hum Genet 2001;69:1401-6.
31. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Presence of four major haplotypes in human BCMA gene: Lack of association with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2001;2:276-9.
32. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms, with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002;3:424-9.
33. Koyama T, Tsukamoto H, Masumoto K et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology 2003;42:980-5.
34. Chicheportiche Y, Chicheportiche R, Sizing I et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: Blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002;4:126-33.
35. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-9.
36. Kaplan MJ, Lewis EE, Sheldon EA et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002;169:6020-9.
37. Pradet-Balade B, Medema JP, Lopez-Fraga M et al. An andogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 2002;21:5711-20.
38. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
39. Amett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
40. Murakami Y, Isogai K, Tomita H et al. Detection of allelic imbalance in the gene expression of hMSH2 or RB1 in lymphocytes from pedigrees of hereditary, nonpolyposis, oolorectal cancer and retinoblastoma by an RNA difference plot. J Hum Genet 2004;49:635-41.
41. DerSimonian R, Laird N. Meta-analysis in Clinical Trials. Control Clin Trials 1986;7:177-188.
42. den Dunnen J. Nomenclature for the description of sequence variations. (http://www.genomic.unimelb.edu.au/md/munomen/)
43. Stohl W, Metyas S, Tan SM et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patents with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1096-103.
44. Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001;2:946-51.
45. Nakayama K. Furin: A mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997;327:625-35.
46. Wallweber HJ, Compaan DM, Starovasnik MA, Hymowitz SG. The crystal structure of a proliferation-inducing ligand, APRIL. J Mol Biol 2004;343:283-90.
47. Hayakawa K, Hardy RR, Parks DR, Herzenberg LA. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med 1983;157:202-18.
48. O'Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma calls. J Exp Med 2004;199:91-8.
49. Jacobi AM, Odendahl M, Reiter K et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42.
50. Hutloff A, Buchner K, Reiter K et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004;50:3211-20.
51. Quintero-Del-Rio AI, Kelly JA, Kilpatrick J, James JA, Harley JB. The genetics of systemic lupus erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p15.6 (SLEN3). Genes Immun 2002;3(Suppl):57-62.
52. Quintero-Del-Rio AI, Kelly JA, Garriott CP et al. SLEN2 (2q34-35) and SLEN1 (10q22.3) replication in systemic lupus erythematosus stratified by nephritis. Am J Hum Genet 2004;75:346-8.
53. Ramos PS, Kelly JA, Gray-McGuire C et al. Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes Immun 2006;7:417-32.